Skip to content

COVID-19 and SARS-CoV-2 Detection in Saliva

SARS -CoV-2 Detection in Saliva Samples: A Test Validation Protocol

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04517682
Enrollment
67
Registered
2020-08-18
Start date
2020-05-21
Completion date
2021-08-05
Last updated
2022-03-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

RNA Virus Infections

Keywords

Detection

Brief summary

This study aims to validate the use of human saliva as a substrate for an assay to detect SARS-CoV-2 and define accuracy, analytical sensitivity and specificity of the TaqPath RT-PCR test.

Detailed description

Investigators will carry out validation of a laboratory assay to detect SARS-CoV-2 nucleic acids in human saliva samples. Data for the validation will include the test results from standard nasopharyngeal (NP) swabs (controls) AND matched saliva samples (experimental group) of individuals who are either known to be infected or at high risk of being infected. Investigators hypothesize that the performance of an assay designed specifically for saliva will not perform differently, as defined by a predetermined margin, from the standard assay performed on NP and other respiratory samples

Interventions

DIAGNOSTIC_TESTRT-PCR

The RT-PCR assay will be performed on paired nasopharyngeal and saliva samples

Sponsors

The Saratoga Hospital
CollaboratorUNKNOWN
St. Joseph Hospital of Orange
CollaboratorOTHER
Crozer-Keystone Health System
CollaboratorOTHER
Ambry Genetics
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Reads and understands English or Spanish * Willing and able to provide consent * Diagnosed with COVID-19 or at high risk of disease based on objective criteria

Exclusion criteria

* Unwilling or unable to provide consent. * Pregnant female

Design outcomes

Primary

MeasureTime frameDescription
Detection of COVID-19 SARs-CoV-2 in saliva samples versus nasopharyngeal samplesup to 7 daysTaqPath RT-PCR assay performed on saliva compared to TaqPath RT-PCR performed on nasopharyngeal samples for assay accuracy, concordance, reproducibility/precision, analytical sensitivity and analytical specificity.

Other

MeasureTime frameDescription
Current symptom statusBaselineParticipant is symptomatic or asymptomatic
Current symptomsBaselineParticipant reports one or more of the following symptoms at baseline. Cough, Shortness of breath or difficulty breathing, fever, chills, muscle pain, sore throat, new loss of taste or smell, any nausea, vomiting or diarrhea.
Reason for testingBaselineParticipants may be recruited from individuals presenting for various indications for testing including; followup testing after previous positive result, at risk healthcare worker, exposure to known positive or symptomatic, public facing worker or workplace hazards, employee based screening.
Date of first symptom or number of days since first symptom.BaselineParticipant reports date of first symptom or number of days since first symptom.
Previous test for COVID-19 and date of test.BaselineParticipant reported result (positive, negative, inconclusive) of previous test for COVID-19 and date of test .
Prior symptomsBaselineParticipant reports one or more of the following symptoms at baseline. Cough, Shortness of breath or difficulty breathing, fever, chills, muscle pain, sore throat, new loss of taste or smell, any nausea, vomiting or diarrhea.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026